![Sophie Pierrin-Lépinard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sophie Pierrin-Lépinard
Direttore/Membro del Consiglio presso ScreenCell SA
Posizioni attive di Sophie Pierrin-Lépinard
Società | Posizione | Inizio | Fine |
---|---|---|---|
ScreenCell SA
![]() ScreenCell SA Miscellaneous Commercial ServicesCommercial Services ScreenCell SA provides access to circulating rare cells. It offers rare cell isolation solutions for medical and research applications. The company was founded by Patrizia Paterlini-Brechot, Ian Jones and Christian Brechot on April 11, 2001 and is headquartered in Sarcelles, France. | Direttore/Membro del Consiglio | 17/02/2011 | - |
BNP Paribas Développement SA
![]() BNP Paribas Développement SA Investment ManagersFinance BNP Paribas Développement SA operates as private equity firm. The company was founded in 1988 and is headquartered in Paris, France. | Investitore di Private Equity | 01/12/2017 | - |
Storia della carriera di Sophie Pierrin-Lépinard
Precedenti posizioni note di Sophie Pierrin-Lépinard
Società | Posizione | Inizio | Fine |
---|---|---|---|
Banexi Ventures Partners SA
![]() Banexi Ventures Partners SA Investment ManagersFinance Banexi Ventures Partners SA is a Venture Capital firm, a subsidiary of Kreaxi SASU founded in 1983. Banexi Ventures Partners SA is headquartered in Paris. | Direttore/Membro del Consiglio | 25/03/2009 | 16/11/2016 |
Membro del Comitato di Investimento | 01/01/1999 | 25/03/2009 | |
Investitore di Private Equity | 01/01/1999 | 16/11/2016 | |
Apoxis SA
![]() Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Corporate Officer/Principal | - | 01/08/2007 |
Antabio SAS
![]() Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Direttore/Membro del Consiglio | - | - |
Kreaxi SASU
![]() Kreaxi SASU Investment ManagersFinance Kreaxi SASU (Kreaxi) is an independent private equity firm born from the merger of Rhône-Alpes Création and Banexi Ventures Partners. The company is headquartered in Paris, France. | Investitore di Private Equity | 01/11/2016 | - |
SYMETIS SA | Direttore/Membro del Consiglio | 11/10/2010 | - |
Formazione di Sophie Pierrin-Lépinard
Université Fédérale Toulouse Midi-Pyrénées | Doctorate Degree |
ESCP Europe Campus Paris | Graduate Degree |
Statistiche
Distribuzione geografica
Francia | 8 |
Svizzera | 3 |
Posizioni
Director/Board Member | 4 |
Private Equity Investor | 3 |
Investment Committee Member | 1 |
Settori
Finance | 4 |
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 7 |
---|---|
BNP Paribas Développement SA
![]() BNP Paribas Développement SA Investment ManagersFinance BNP Paribas Développement SA operates as private equity firm. The company was founded in 1988 and is headquartered in Paris, France. | Finance |
Apoxis SA
![]() Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Health Technology |
Banexi Ventures Partners SA
![]() Banexi Ventures Partners SA Investment ManagersFinance Banexi Ventures Partners SA is a Venture Capital firm, a subsidiary of Kreaxi SASU founded in 1983. Banexi Ventures Partners SA is headquartered in Paris. | Finance |
Symetis SA
![]() Symetis SA BiotechnologyHealth Technology Symetis SA develops minimally invasive heart valve replacement devices. Its products include ACURATE TA and ACURATE neo. The company was founded by Simon P. Hoerstrup and Gregor Zünd on September 5, 2001 and is headquartered in Ecublens, Switzerland. | Health Technology |
ScreenCell SA
![]() ScreenCell SA Miscellaneous Commercial ServicesCommercial Services ScreenCell SA provides access to circulating rare cells. It offers rare cell isolation solutions for medical and research applications. The company was founded by Patrizia Paterlini-Brechot, Ian Jones and Christian Brechot on April 11, 2001 and is headquartered in Sarcelles, France. | Commercial Services |
Antabio SAS
![]() Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Health Technology |
Kreaxi SASU
![]() Kreaxi SASU Investment ManagersFinance Kreaxi SASU (Kreaxi) is an independent private equity firm born from the merger of Rhône-Alpes Création and Banexi Ventures Partners. The company is headquartered in Paris, France. | Finance |